106 related articles for article (PubMed ID: 38716597)
1. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
[No Abstract] [Full Text] [Related]
2. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
3. Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1
Liu HC; Huang YJ; Jaing TH; Wu KH; Chen SH; Wang SC; Yeh TC; Hsiao CC; Chang TK; Yen HJ; Huang FL; Lin PC; Hou JY; Sheen JM; Liao YM; Chang TY; Chen YC; Chiou SS; Yang CP; Pui CH; Liang DC; Shih LY
Br J Haematol; 2024 Apr; 204(4):1344-1353. PubMed ID: 38479427
[TBL] [Abstract][Full Text] [Related]
4. IKZF1
Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
[TBL] [Abstract][Full Text] [Related]
5. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of IKZF1 deletions and IKZF1
Braun M; Pastorczak A; Sędek Ł; Taha J; Madzio J; Jatczak-Pawlik I; Wypyszczak K; Matysiak M; Derwich K; Lejman M; Kazanowska B; Szczepański T; Kowalczyk JR; Mlynarski W;
Hematol Oncol; 2022 Aug; 40(3):430-441. PubMed ID: 35118711
[TBL] [Abstract][Full Text] [Related]
7. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.
Yao QM; Liu KY; Gale RP; Jiang B; Liu YR; Jiang Q; Jiang H; Zhang XH; Zhang MJ; Chen SS; Huang XJ; Xu LP; Ruan GR
BMC Cancer; 2016 Apr; 16():269. PubMed ID: 27067989
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
Michels N; Boer JM; Enshaei A; Sutton R; Heyman M; Ebert S; Fiocco M; de Groot-Kruseman HA; van der Velden VHJ; Barbany G; Escherich G; Vora A; Trahair T; Dalla-Pozza L; Pieters R; Zur Stadt U; Schmiegelow K; Moorman AV; Zwaan CM; den Boer ML
Lancet Haematol; 2021 Oct; 8(10):e700-e710. PubMed ID: 34560013
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic significance of IKZF1 gene deletions in patients with B-cell acute lymphoblastic leukemia].
Tang BQ; Cai ZH; Lin DN; Wang ZX; Liang XJ; Fan ZP; Huang F; Liu QF; Zhou HS
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):235-240. PubMed ID: 35405782
[No Abstract] [Full Text] [Related]
11. Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
Li H; Zhang W; Kuang P; Ye Y; Yang J; Dai Y; Lu X; Zheng Y; Liu T
Leuk Lymphoma; 2018 Aug; 59(8):1890-1898. PubMed ID: 29214878
[TBL] [Abstract][Full Text] [Related]
12. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.
Waanders E; van der Velden VH; van der Schoot CE; van Leeuwen FN; van Reijmersdal SV; de Haas V; Veerman AJ; van Kessel AG; Hoogerbrugge PM; Kuiper RP; van Dongen JJ
Leukemia; 2011 Feb; 25(2):254-8. PubMed ID: 21102428
[TBL] [Abstract][Full Text] [Related]
13. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
[TBL] [Abstract][Full Text] [Related]
14. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia.
Mangum DS; Meyer JA; Mason CC; Shams S; Maese LD; Gardiner JD; Downie JM; Pei D; Cheng C; Gleason A; Luo M; Pui CH; Aplenc R; Hunger SP; Loh M; Greaves M; Trede N; Raetz E; Frazer JK; Mullighan CG; Engel ME; Miles RR; Rabin KR; Schiffman JD
JAMA Oncol; 2021 Oct; 7(10):1521-1528. PubMed ID: 34410295
[TBL] [Abstract][Full Text] [Related]
15. Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.
Kim M; Park J; Kim DW; Kim YJ; Jeon YW; Yoon JH; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim HJ; Min CK; Cho SG; Kim Y; Lee JW; Han K; Min WS; Lee S
Bone Marrow Transplant; 2015 Mar; 50(3):354-62. PubMed ID: 25501350
[TBL] [Abstract][Full Text] [Related]
16. [Effect of increasing the intensity of chemotherapy on the prognosis of acute lymphoblastic leukemia in children with IKZF1 deletion].
Zheng YZ; Li J; LE SH; Zheng H; Hua XL; Chen ZS; Hu JD
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Jul; 21(7):690-695. PubMed ID: 31315770
[TBL] [Abstract][Full Text] [Related]
17. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract][Full Text] [Related]
18. Aberrant IKZF1 gene as relapse predictor in standard-risk pediatric patients with B-cell precursor acute lymphoblastic leukaemia.
Vshyukova VS; Krasko OV; Yanchanka DA; Meleshko AN
Int J Lab Hematol; 2022 Aug; 44(4):769-776. PubMed ID: 35505470
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis.
Zhang W; Kuang P; Li H; Wang F; Wang Y
Ann Hematol; 2017 Feb; 96(2):215-225. PubMed ID: 27815723
[TBL] [Abstract][Full Text] [Related]
20. [A retrospective comparative study of haplotype hematopoietic stem cell transplantation and human leukocyte antigen-matched sibling donor hematopoietic stem cell transplantation in the treatment of acute B-lymphocyte leukemia].
Wang ZD; Sun YQ; Yan CH; Wang FR; Mo XD; Lyu M; Zhao XS; Han W; Chen H; Chen YY; Wang Y; Xu LP; Wang YZ; Liu YR; Cheng YF; Zhang XH; Liu KY; Huang XJ; Chang YJ
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):221-228. PubMed ID: 35405780
[No Abstract] [Full Text] [Related]
[Next] [New Search]
